Industry
Biotechnology
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
July 25, 2024 | 10:41 am
Portfolio Pulse from Benzinga Newsdesk
June 21, 2024 | 11:05 am
Portfolio Pulse from Benzinga Newsdesk
June 20, 2024 | 3:25 pm
Portfolio Pulse from Avi Kapoor
June 20, 2024 | 9:29 am
Portfolio Pulse from Benzinga Insights
May 31, 2024 | 3:30 pm
Portfolio Pulse from Benzinga Newsdesk
May 31, 2024 | 12:39 pm
Portfolio Pulse from Avi Kapoor
May 16, 2024 | 9:40 am
Portfolio Pulse from Benzinga Newsdesk
May 15, 2024 | 2:57 pm
Portfolio Pulse from Benzinga Newsdesk
May 15, 2024 | 10:45 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.